B.Riley reiterates Buy on Ovid Therapeutics stock, $5 target By Investing.com

Ovid reported Q4 EPS $0.06 vs consensus -$0.1137 (152.77% surprise) and revenue $718K vs $80.7K (≈+790%), a material beat. B.Riley reiterated Buy and Leerink maintained Outperform with $5 price targets; shares have risen 434% Y/Y to $2.30 (market cap ~$300M) and the company holds $150M pro forma cash with runway into 2029. Clinical catalysts include OV329 pediatric expansion Phase 2 (60 subjects, 8-week) with results ~mid-2027, an open-label PPR study (12–20 subjects) starting Q3‑2026 with results likely Q4‑2026, OV4071 Phase 1 on track for Q2‑2026, which supports continued stock-specific volatility.

Analysis

Market moves appear to be pricing a de-risking of clinical development rather than incremental scientific validation; that creates a binary payoff where a single positive signal will re-rate the equity materially while any safety signal or ambiguous biomarker readout can erase gains. Because liquidity is thin, flows from retail and algorithmic momentum strategies can amplify moves on relatively small news items, increasing short-term volatility and making timing around readouts as important as conviction in the underlying science.

Second-order winners include CROs and specialty formulation manufacturers that can scale pediatric liquid formulations and qEEG services — those supply-chain bottlenecks can create execution risk and disclosure-driven milestones for the company or potential partners. The platform nature of the KCC2 program also raises the probability of non-dilutive deal activity (co-development or licensing) versus a straight commercial-scale exit; acquirers will value translatable biomarkers (qEEG) more highly if they reduce Phase 2→3 uncertainty.

Primary tail risks are classic binary-biotech: enrollment delays, regulatory skepticism of surrogate endpoints, and the funding cliff if multiple programs advance concurrently. Given elevated implied volatility and thin options markets, capital efficiency favors defined-loss option structures or concentrated equity with tight hedges rather than naked long gamma. Watch the next three to nine months for incremental, non-binary disclosures (safety cohorts, pharmacodynamics) that will re-price probability rather than deliver final proof.

Key Decisions for Investors

• Tactical long equity (OVID) — size 0.8–1.2% portfolio. Enter on a liquidity window (VWAP day or block) and hold through the next incremental safety/PD readouts (3–9 months). Risk: full equity loss if pivotal fails; Reward: asymmetric upside (target 2.5–4x) if data validates target engagement and clears regulatory path. Use a protective stop or buy a 3–6 month put (cost <25% of position) to cap downside.
• Defined‑risk options spread (OVID) — buy 18-month call spread to limit premium decay. Example structure: buy LEAPS call ~12–18 months out and finance by selling a higher strike call to reduce net debit (size 0.5% portfolio). Objective: capture re-rate into a potential partnership/label expansion while capping downside to the net premium (expect 3–6x return on success).
• Idiosyncratic pair trade to isolate program upside — go long OVID (0.8% portfolio) and short XBI (0.8% portfolio) for 3–9 months to neutralize macro biotech beta. This isolates clinical/regulatory upside while protecting against sector-wide volatility. Risk: XBI underperformance harms returns if sector rallies materially; rebalance monthly.
• Event hedge / optionality sell — if implied vol spikes into a headline readout, favor selling a short-dated call spread (30–45 days) to harvest inflated premium rather than naked exposure. Keep position sizes small (max 0.25% portfolio) and avoid assignment risk by rolling or closing before expiration.